ScreenerHero

SRPT Sarepta Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sarepta.com
17.50USD+1.10%Mkt Cap: 1.85B $P/E: —

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.85B USD
Enterprise Value2.10B USD
Revenue (TTM)1.97B USD
Gross Profit1.36B USD
Net Income (TTM)-713.41M USD
Revenue/Share19.00 USD
Last Price17.50 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees835
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)7.18
PEG-0.09
EV/EBITDA-119.91
EV/Revenue1.06
P/S0.93
P/B1.20
EPS (TTM)-1.57
EPS (Forward)2.41
52W Range
14.6926% of range25.32
52W High25.32 USD
52W Low14.69 USD
Profitability
Gross Margin61.81%
Oper. Margin13.03%
EBITDA Margin-0.89%
Profit Margin-32.45%
ROE-62.55%
ROA-21.30%
Growth
Revenue Growth-34.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-205.48M USD
CapEx (TTM)109.85M USD
FCF Margin1.12%
FCF Yield1.20%
Net Debt273.92M USD
Net Debt/EBITDA-15.62
Balance Sheet
Debt/Equity0.91
Current Ratio4.42
Quick Ratio2.44
Book Value/Sh14.46 USD
Cash/Share7.46 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJul 12, 2012
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.73 USD
Upside (mean)+24.2%
Target Range5.000 USD – 38.00 USD
5.000+24.2% to mean38.00
# Analysts22
Ownership
Shares Out.105.63M
Float100.54M
Insiders4.89%
Institutions104.10%
Short Interest
Short Ratio8.2d
Short % Float28.86%
Short % Out.24.08%
Shares Short25.43M
Short (prev mo.)27.05M
Technical
SMA 5018.92 (-7.5%)
SMA 20019.07 (-8.2%)
Beta0.38
S&P 52W Chg16.45%
Avg Vol (30d)2.81M
Avg Vol (10d)2.45M
Technical Indicators
RSI (14)40.6
MACD-0.4950
MACD Signal-0.1506
MACD Hist.-0.3444
BB Upper22.56 USD
BB Middle19.35 USD
BB Lower16.15 USD
BB Width33.11%
ATR (14)1.005 USD
Vol Ratio (20d)1.00x